Home  >  Research  >  Labs  >  Cancer Program  >  CANCER EPIGENETICS

RESEARCH OVERVIEW

The Cancer Epigenetics Laboratory is a multidisciplinary group that focuses on the development of novel approaches to target cancers that are currently refractory to treatment and associated to poor outcome, such as triple negative breast cancers and serious ovarian cancers. At present, there are no targeted approaches to combat these tumors, with chemotherapy and radiation the only treatment options. The laboratory generates novel functionalised molecules able to specifically target these tumors with minimal toxicity to normal cells. Our emphasis is in advanced stage metastatic tumors, which quasi invariably develop resistance. Ultimately we wish to revert the behaviour of metastatic cells by sensitising these treatment resistant tumors to chemotherapy regimes.

The lab deploys state-of-the art precision medicine tools to specifically re-engineer the genome and the epigenome of cancer cells, to restore mitotically hereditable (normal-like) features. Tools currently employed by the lab members include artificial genome engineering proteins (e.g made of zinc fingers, CRISPR/dCas9 backbones) attached to a library of effector domains for epigenomic editing.

The lab has patented and developed interference peptide technology, small synthetic and functionalised cell-penetrating peptides programmed to inhibit oncogenic transcription factors overexpressed in metastatic cells. By blocking or inhibiting essential protein-protein interactions we promote potent and selective apoptosis in metastatic breast cancer cells while sensitizing these tumors to chemotherapy regimes. Lastly, we collaborate with nanotechnology investigators (S. Iyer, UWA & Leaf Huang, UNC) to encapsulate these agents using targeted nanoparticles.

Associate Professor Pilar Blancafort

Associate Professor Pilar Blancafort

Cancer Epigenetics (Program Head - Cancer)

Read more

LATEST NEWS

Dr Ankur Sharma in front of MRI image at Harry Perkins Institute of Medical Research

New liver cancer blood test gets $2.5m research funding boost

Predicting relapse for one of the world's deadliest cancers. Perth cancer researchers are on track to improve the outcomes of patients with the most common type of primary liver cancer. Hepatocellular carcinoma (HCC) is one of the most aggressive cancer types. Patients typically suffer a high rate of treatment failures.…

Read More
people in lab coats inside a cancer laboratory

ACRF Centre for Advanced Cancer Genomics opens in Perth

Latest technology analyses WA cancer patient tumours. The Australian Cancer Research Foundation (ACRF) Centre for Advanced Cancer Genomics, housing the next generation DNA sequencing technology, was opened today at the Harry Perkins Institute of Medical Research by the Federal Member for Curtin, Ms Kate Chaney. ACRF CEO, Kerry Strydom, in…

Read More
Prof Peter Leedman Ao, Director of the Harry Perkins Institute of Medical Research

WA joins national call to improve cancer outcomes

Fast Facts Cancer is a leading cause of death by disease in adults and children in Australia More than 145,000 Australians were diagnosed with cancer in 2020 In 2020 nearly 50,000 Australians died from cancer Cancer was the leading cause of death for children aged 1–14 between 2015– 2017 Cancer…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS